Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to Post FY2024 Earnings of $1.33 Per Share, Zacks Research Forecasts

Posted by Defense World Staff on Sep 25th, 2023

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) – Research analysts at Zacks Research raised their FY2024 earnings per share estimates for Catalyst Pharmaceuticals in a research report issued on Friday, September 22nd. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $1.33 per share for the year, up from their previous estimate of $1.32. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $0.87 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.40 EPS and FY2025 earnings at $1.63 EPS.

CPRX has been the topic of a number of other reports. Piper Sandler lifted their price objective on Catalyst Pharmaceuticals from $21.00 to $24.00 in a research note on Wednesday, June 21st. HC Wainwright reissued a “buy” rating and issued a $24.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, August 11th. StockNews.com began coverage on Catalyst Pharmaceuticals in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $27.00 price target on shares of Catalyst Pharmaceuticals in a research note on Tuesday, August 22nd. Finally, Truist Financial boosted their price target on Catalyst Pharmaceuticals from $22.00 to $24.00 in a research note on Tuesday, June 20th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.75.

View Our Latest Research Report on CPRX

Catalyst Pharmaceuticals Price Performance

Catalyst Pharmaceuticals stock opened at $12.10 on Monday. The stock’s 50 day moving average is $13.66 and its 200 day moving average is $14.17. The firm has a market cap of $1.29 billion, a P/E ratio of 11.98 and a beta of 1.11. Catalyst Pharmaceuticals has a one year low of $11.09 and a one year high of $22.11.

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.08. The company had revenue of $99.58 million for the quarter, compared to analyst estimates of $92.77 million. Catalyst Pharmaceuticals had a return on equity of 36.13% and a net margin of 38.14%.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. HRT Financial LP increased its holdings in shares of Catalyst Pharmaceuticals by 551.5% during the first quarter. HRT Financial LP now owns 222,178 shares of the biopharmaceutical company’s stock valued at $3,683,000 after acquiring an additional 188,073 shares in the last quarter. Sheaff Brock Investment Advisors LLC bought a new stake in Catalyst Pharmaceuticals during the first quarter worth $175,000. Capital Impact Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 3.4% during the first quarter. Capital Impact Advisors LLC now owns 46,096 shares of the biopharmaceutical company’s stock worth $764,000 after buying an additional 1,497 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 122.0% during the first quarter. Nisa Investment Advisors LLC now owns 2,820 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 1,550 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. grew its holdings in Catalyst Pharmaceuticals by 50.0% during the first quarter. Hussman Strategic Advisors Inc. now owns 93,000 shares of the biopharmaceutical company’s stock worth $1,542,000 after buying an additional 31,000 shares in the last quarter. Institutional investors own 77.27% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

(Get Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.